Protagonist Therapeutics Business Summary

Protagonist Therapeutics, Inc. (PTGX) is a late-stage biopharmaceutical company that generates revenue through a high-margin licensing and collaboration model, leveraging its proprietary peptide technology platform to develop oral alternatives to injectable biologics. The company’s primary business segments are focused on hematology and inflammatory diseases, anchored by two potential blockbuster assets: rusfertide, a first-in-class hepcidin mimetic for polycythemia vera (PV) co-developed with Takeda, and icotrokinra (JNJ-2113), an oral IL-23 receptor antagonist licensed to Johnson & Johnson for psoriasis and ulcerative colitis. With New Drug Applications (NDAs) submitted for both lead candidates as of early 2026, Protagonist is transitioning toward a commercial-stage entity supported by significant milestone payments and tiered royalty streams. Its direct competitors include Incyte Corporation, AbbVie Inc., and Novartis AG; Protagonist distinguishes itself by utilizing a de novo peptide discovery engine to target validated pathways that were previously only accessible via large-molecule injectable therapies. The company was founded by Dr. Dinesh V. Patel, Dr. Christian Schafmeister, and Dr. Mark L. Smythe, utilizing foundational technology from the University of Queensland. The current leadership team is headed by President and CEO Dr. Dinesh V. Patel, who brings over 35 years of executive experience from Arête Therapeutics and Vicuron Pharmaceuticals. Key officers include Dr. Mohammad Masjedizadeh (EVP & Chief Technical Officer), Dr. Arturo Molina (Chief Medical Officer), and Asif Ali (EVP & Chief Financial Officer). The board is chaired by Dr. Harold Selick and includes notable clinical advisor Dr. Samuel Saks, a co-founder of Jazz Pharmaceuticals. Protagonist is backed by prominent institutional investors, including RTW Investments, Farallon Capital Management, and BlackRock, maintaining a robust cash runway through 2028 to support its expanding pipeline in obesity and metabolic disorders.